|
|
||||||||
From the Departments of Preventive Medicine and Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, and the Veterans Administration Hospital, St. Louis, Missouri 63106
Abstract
NZB/NZW F1 mice that received from birth prolonged high dose administration of SDNA-poly-d-lysine, or intermittent SDNA-poly-d-lysine followed by cyclophosphamide lived significantly longer than their controls. In association with the increased survival the following alterations in laboratory parameters were observed: decreased levels of anti-DNA antibodies, decreased numbers of spleen plaque-forming cells against DNA-coated RBC, less histologic and immunofluorescent evidence of glomerulonephritis, and less IgG in kidney eluates. The results suggest that tolerance to SDNA will increase survival and decrease tissue lesions.
Footnotes
1 This work was supported in part by United States Public Health Service, Arthritis and Metabolism Branch, Grants AM 05548 and AM 08490. This work was presented in part at the 37th Annual Meeting of The American Rheumatism Association Section of the Arthritis Foundation, June 1973.
2 Please send reprint requests to: Dr. Lewis P. Parker, Preventive Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
3 Staff Physician MRIS #3275, Veterans Administration Hospital, St. Louis, Missouri 63106.
4 Professor of Medicine, McGill University School of Medicine, Montreal.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |